CALLS TO ACTION

CIAAG issued a Call to Action, asking our members, to send a copy of our correspondence to the FDA outlining our concerns with the issuance of an IRB Waiver/Alteration of Informed Consent for Human Clinical Trials issued in 2017.

CIAAG issued a Call to Action, asking oour members to contact their lawmakers and request support for the FDA to put the IRB Waiver/Alternation of Informed Consent for Human Clinical Trials, regulatory change, on the Federal Register and permit the collection of public feedback, post-fact. This is something that should have taken place in 2017 when the change was issued. Given the gravity of this change, the public should have been permitted the opportunity to provide their feedback.

CIAAG issued a Call to Action, asking our members, to forward CIAAG's correspondence to the DEA too their federal lawmakers, asking for their support for the creation of a federal committee to review the supply chain issues related to opioid analgesics medications, and for the development of policy recommendations to address any gaps or inconsistencies in current policy guidance.

CIAAG issued a Call to Action, asking our members to forward our correspondence to their lawmakers, asking for their support for the FDA and it's partners, to provide the public transparency on their activities.